propyl 2-tert-butyl-3-cyclohexylmethylimidazo[1,2-c]pyrimidine-7-carboxylate | 1011803-71-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并[1，2-a]嘧啶
• 英文名称: propyl 2-tert-butyl-3-cyclohexylmethylimidazo[1,2-c]pyrimidine-7-carboxylate
• 英文别名: 2-tert-butyl-3-cyclohexylmethylimidazo[1,2-c]pyrimidine-7-carboxylic acid propyl ester；propyl 2-tert-butyl-3-(cyclohexylmethyl)imidazo[1,2-c]pyrimidine-7-carboxylate
• CAS: 1011803-71-6
• 化学式: C₂₁H₃₁N₃O₂
• 分子量: 357.496
• InChiKey: MBGCMOXQCIMZOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  propyl 2-tert-butyl-3-cyclohexylmethylimidazo[1,2-c]pyrimidine-7-carboxylate 在 lithium hydroxide monohydrate 、 水 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以80%的产率得到2-tert-butyl-3-cyclohexylmethylimidazo[1,2-c]pyrimidine-7-carboxylic acid
  参考文献：
  名称：

  RING-FUSED HETEROCYCLIC DERIVATIVE

  摘要：

  公开号：

  EP2671582B1
• 作为产物：
  描述：

  propyl 6-aminopyrimidine-4-carboxylate 、 2-bromo-1-cyclohexyl-4,4-dimethylpentan-3-one 以21%的产率得到propyl 2-tert-butyl-3-cyclohexylmethylimidazo[1,2-c]pyrimidine-7-carboxylate
  参考文献：
  名称：

  EP2070927

  摘要：

  公开号：

文献信息

• Fused heterocycle derivative
  申请人：Sawada Takashi

  公开号：US20090239853A1

  公开（公告）日：2009-09-24

  A fused heterocycle derivative represented by the general formula (I): (wherein R 1 represents optionally substituted lower alkyl, or the like; R 2 represents an optionally substituted aliphatic heterocyclic group, or the like; R 3 represents —C(=Z)NR 5 R 6 (wherein R 5 and R 6 represent optionally substituted lower alkyl, or the like, and Z represents an oxygen atom or the like), or the like; n represents an integer of 1 to 3; and W represents C—R 5 (wherein R 5 represents a hydrogen atom or the like)) or a pharmaceutically acceptable salt thereof, and the like are provided.

  提供一种由通式（I）表示的融合杂环衍生物：（其中R1代表可选取代的低碳基等；R2代表可选取代的脂肪族杂环基等；R3代表—C（=Z）NR5R6（其中R5和R6代表可选取代的低碳基等，Z代表氧原子等）等；n代表1到3的整数；W代表C—R5（其中R5代表氢原子等）或类似物的药物可接受的盐等。
• Ring-fused heterocyclic derivative
  申请人：Sawada Takashi

  公开号：US09000186B2

  公开（公告）日：2015-04-07

  A ring-fused heterocyclic derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof having a T-type calcium channel regulatory effect and useful as a pruritus therapeutic and/or preventive agent, and the like are provided. In the general formula (I), R1 represents optionally substituted lower alkyl, and the like; R2 represents an optionally substituted cycloalkyl, and the like; Q represents a hydrogen atom, and the like; R3 represents —C(═O)NR8R9 (wherein R8 and R9 may be the same or different, and each represents a hydrogen atom, and the like), and the like; L1 represents —CR11AR11B— (wherein R11A and R11B may be the same or different, and each represents a hydrogen atom, and the like), and the like; and W1 and W2 may be the same or different, and each represents C—R12 (wherein R12 represents a hydrogen atom, and the like), and the like.

  提供一种由以下一般式（I）表示的环融合杂环衍生物或其药学上可接受的盐，具有T型钙通道调节作用，可用作瘙痒治疗和/或预防剂等。在一般式（I）中，R1代表可选取代的较低烷基等；R2代表可选取代的环烷基等；Q代表氢原子等；R3代表—C（═O）NR8R9（其中R8和R9可以相同或不同，每个代表氢原子等）等；L1代表—CR11AR11B—（其中R11A和R11B可以相同或不同，每个代表氢原子等）等；W1和W2可以相同或不同，每个代表C—R12（其中R12代表氢原子等）等。
• FUSED HETEROCYCLIC DERIVATIVE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2070927A1

  公开（公告）日：2009-06-17

  A fused heterocycle derivative represented by the general formula (I): (wherein R1 represents optionally substituted lower alkyl, or the like; R2 represents an optionally substituted aliphatic heterocyclic group, or the like; R3 represents -C(=Z)NR5R6 (wherein R5 and R6 represent optionally substituted lower alkyl, or the like, and Z represents an oxygen atom or the like), or the like; n represents an integer of 1 to 3; and W represents C-R5 (wherein R5 represents a hydrogen atom or the like)) or a pharmaceutically acceptable salt thereof, and the like are provided.

  通式 (I) 所代表的融合杂环衍生物： (其中 R1 代表任选取代的低级烷基或类似物；R2 代表任选取代的脂肪杂环基团或类似物；R3 代表-C(=Z)NR5R6（其中 R5 和 R6 代表任选取代的低级烷基或类似物，Z 代表氧原子或类似物）或类似物；n 代表 1 至 3 的整数；W 代表 C-R5（其中 R5 代表氢原子或类似物））或其药学上可接受的盐等。
• US8236841B2
  申请人：——

  公开号：US8236841B2

  公开（公告）日：2012-08-07